Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: From early reduction in reocclusion to improved long-term clinical outcome

American Heart Journal

Volumn 157, Issue 3, 2009, Pages 532-540

  van den Bergh, Paul J P C ^a   Kievit, Peter C ^a   Brouwer, Marc A ^a   Aengevaeren, Wim R M ^a   Veen, Gerrit ^b   Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COUMARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEPARINIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ASPIRIN; CORONARY OCCLUSION; COUMARINS; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MYOCARDIAL INFARCTION; RECURRENCE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 60749086470     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.11.008     Document Type: Article

References (35)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
3. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
4. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
5. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
6. Wallentin L., Wilcox R.G., Weaver W.D., et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362 (2003) 789-797
7. Andreotti F., Testa L., Biondi-Zoccai G.G., et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27 (2006) 519-526
8. Brouwer M.A., van den Bergh P.J.P.C., Aengevaeren W.R.M., et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis (APRICOT)-2 trial. Circulation 106 (2002) 659-665
9. Ohman E.M., Califf R.M., Topol E.J., et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 82 (1990) 781-791
10. Brouwer M.A., Kievit P.C., Dieker H., et al. Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival: observations from the APRICOT trial. Am Heart J 155 (2008) 1039-1046
11. Brouwer M.A., Böhncke J.R., Veen G., et al. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 26 (1995) 1440-1444
12. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 312 (1985) 932-936
13. Ambrose J.A., Winters S.L., Arora R.R., et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 6 (1985) 1233-1238
14. Morrow D.A., Antman E.M., Charlesworth A., et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102 (2000) 2031-2037
15. Roux S., Christeller S., and Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 19 (1992) 671-677
16. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
17. Meijer A., Verheugt F.W.A., Werter C.J., et al. Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 87 (1993) 1524-1530
18. White H.D., French J.K., Hamer A.W., et al. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. J Am Coll Cardiol 25 (1995) 218-223
19. Williams M.J.A., Morison I.M., Parker J.H., et al. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 30 (1997) 364-369
20. Granger C.B., Hirsch J., Califf R.M., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation 93 (1996) 870-878
21. Brouwer M.A., and Verheugt F.W.A. Oral anticoagulation for acute coronary syndromes. Circulation 105 (2002) 1270-1274
22. Cromheecke M.E., Levi M., Colly L.P., et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 356 (2000) 97-102
23. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
24. Wallentin L., Bergstrand L., Dellborg M., et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J 24 (2003) 897-908
25. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
26. HERO-2 investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 trial. Lancet 358 (2001) 1855-1863
27. The OASIS-6 trial group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
28. Brouwer M.A., Clappers N., and Verheugt F.W.A. Adjunctive treatment in patients treated with thrombolytic therapy. Heart 90 (2004) 581-588
29. Antman E.A., Morrow D., McCabe C., et al. Enoxaparin versus unfractionated heparin for ST-elevation myocardial infarction-one year results from EXTRACT TIMI-25. Presented at European Society of Cardiology Congress, Vienna (2007)
30. Testa L., Biondi Zoccai G., Porto I., et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 99 (2007) 1637-1642
31. Kievit P.C., Brouwer M.A., Veen G., et al. High-grade infarct related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction. Am Heart J 148 (2004) 826-833
32. Michels K.B., and Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 91 (1995) 476-485
33. Collet J.P., Montalescot G., Le May M., et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol 48 (2006) 1326-1335
34. King III S.B., Smith Jr. S.C., Hirshfeld J.W., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 51 (2008) 172-209
35. Silber S., Albertsson P., Fernandez-Avilés F., et al. The task force for percutaneous coronary interventions for the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 26 (2005) 804-847